TO901317 suppresses FOXM1 expression and proliferation in HepG2 cells

您当前的位置：

首页 >

文章列表页 >

TO901317 suppresses FOXM1 expression and proliferation in HepG2 cells

更新时间：2025-01-15

|

- TO901317 suppresses FOXM1 expression and proliferation in HepG2 cells
- Journal of Army Medical University Vol. 33, Issue 22, Pages: 2345-2348(2011)
- 作者机构：
  
  第三军医大学基础医学部生物化学与分子生物学教研室
- 作者简介：
- 基金信息：
- DOI：
  CLC： R394.3;R735.7;R730.23
- Published：2011，
  
  Published Online：30 November 2011，
- 稿件说明：
移动端阅览
HU CHANGJIANG, ZHANG YAN, HUANG GANG, et al. TO901317 suppresses FOXM1 expression and proliferation in HepG2 cells. [J]. Journal of army medical university, 2011, 33(22): 2345-2348.
DOI：

HU CHANGJIANG, ZHANG YAN, HUANG GANG, et al. TO901317 suppresses FOXM1 expression and proliferation in HepG2 cells. [J]. Journal of army medical university, 2011, 33(22): 2345-2348. DOI：

摘要

目的探讨肝X受体（liver X receptors，LXR）特异性激动剂TO901317对HepG2细胞中叉头盒蛋白M1（forkhead box protein M1，FOXM1）的表达及对HepG2细胞的增殖及细胞周期的影响。方法 TO901317（终浓度分别为0.5、5 μmol/L）处理HepG2细胞24 h后，采用RT-PCR和Western blot检测FOXM1 mRNA和蛋白表达情况；采用流式细胞术检测细胞周期的变化，并用CCK-8检测HepG2细胞增殖情况。结果经不同浓度的TO901317（终浓度0.5、5 μmol/L）处理HepG2细胞24 h后，FOXM1 mRNA和蛋白表达呈剂量依赖性下调（

P

<

0.05）；流式细胞仪检测结果显示，对照组G

1

期细胞数占间期所有细胞数的百分比为(52.98±2.53)%、0.5 μmol/L TO901317处理组为(61.32±2.36)%、5 μmol/L TO901317处理组为(70.40±4.65)%，表明TO901317能够剂量依赖性诱导HepG2细胞G

1

期阻滞（

P

<

0.05）；CCK-8检测结果显示，对照组

D

(450)为(1.53±0.07)、0.5 μmol/L TO901317处理组为(1.25±0.09)、5 μmol/L TO901317处理组为(1.06±0.06)，表明TO901317能够剂量依赖性抑制HepG2细胞增殖（

P

<

0.05）。结论肝X受体诱导HepG2细胞的G

1

期阻滞，并且抑制该细胞的增殖，其原因之一可能由于抑制了细胞周期蛋白关键调节因子FOXM1的表达。

Abstract

Objective To investigate the effect of treatment of live X receptors specific agonist TO901317 on the expression of FOXM1 and the cell cycle and proliferation in HepG2 cells. Methods HepG2 cells were treated for 24 h with DMSO and 0.5 or 5 μmol/L TO901317.

RT-PCR and Western blotting was taken to detect the FOXM1 expression at mRNA and protein levels. Cell cycle analysis was examined by flow cytometry and cell proliferation was determined by cell counting kit-8 (CCK-8). Results FOXM1 mRNA and protein expression were remarkably reduced after the treatment of TO901317 at different concentrations (

P

<

0.05). The percentage of cells at G

1

stage were (61.32±2.36)% and (70.40±4.65)% respectively after 0.5 and 5 μmol/L TO901317 treatment

significantly higher than that of the control group (

P

<

0.05). The OD value at 450 nm was 1.25±0.09 and 1.06±0.06 respectively after 0.5 and 5 μmol/L TO901317 treatment

significantly lower than the control group (1.53±0.07

P

<

0.05). TO901317 notablely inhibited the HepG2 cells proliferation. Conclusion TO901317 could suppress HepG2 proliferation and induce cell arrest at G

1

cycle in a does-dependent manner

and it may be result from the downregulation of FOXM1

which is one of the key transcription regulators of cell cycle proteins.

关键词

TO901317叉头盒蛋白M1HepG2细胞

Keywords

TO901317forkhead box protein M1HepG2 cells

references

0

Views

0

下载量

0

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Related Articles

Dihydromyricetin improves triglyceride accumulation in HepG2 cells by regulating SIRT1 signaling pathway

Mibefradil improves insulin-resistance HepG2 cells by down-regulating FoxO1 expression

Resveratrol improves lipid droplet lipolysis via up-regulating PKA-PLIN2 pathway in HepG2 cells

CD36 knockdown alleviates lipid accumulation induced by tumor necrosis factor-α and interleukin-6 in HepG2 cells

Related Author

LIAN Jiqin

HE Fengtian

YAN Xiaojing

CHEN Lingxi

LI Tao

SUN Liangbo

ZHANG Yueting

XIAO Hanxi

Related Institution

Department of Biochemistry and Molecular Biology, College of Basic Medical Sciences, Army Medical University (Third Military Medical University)

Department of Nutrition and Food Hygiene, Chongqing Key Laboratory of Nutrition and Food Safety, Chongqing Research Center for Medical Nutrition, College of Military Preventive Medicine, Third Military Medical University

State Key Laboratory of Trauma, Burns and Combined Injury, Department 1, Institute of Surgery Research, Daping Hospital, Third Military Medical University

Department of Endocrinology, Laboratory Center, Department of Integrated Chinese and Western Medicine, Xinqiao Hospital, Third Military Medical University

Department for Nutrition and Food Safety, Chongqing Center of Medical Nutrition, Chongqing Key Laboratory of Nutrition and Food Safety, College of Military Preventive Medicine, Third Military Medical University

⁰